PATENT CLAIM ANALYSIS

Application Number: 16176233
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-04
Patent Classification: ["514", "653000"]

Abstract:
The present invention relates to pharmaceutical compositions comprising a 2-amino-2-[2-(4-C 2-20 -alkyl-phenyl)ethyl]propane-1,3-diol compound or a pharmaceutically acceptable salt thereof, and to the use thereof for treating, preventing or delaying the progression of multiple sclerosis in a pediatric patient or a patient suffering from a specific condition.

Claim (Index 7):
A composition according to  claim 1 , further comprising a co-agent which is selected from interferons, altered peptide ligands, immunosuppressants, adenosine deaminase inhibitors, IV immunoglobulin G, monoclonal antibodies to various T-cell surface markers, TH2 promoting cytokines, antispasticity agents, AMPA glutamate receptor antagonists, inhibitors of VCAM-1 expression or antagonists of its ligand, anti-Macrophage migration inhibitory factor (Anti-MIF), Cathepsin S inhibitors, and mTor inhibitors.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 97.0
- Lexical Diversity: 1.23913
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15986992', '12682343', '15545800', '14631102', '14009241']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7365222845853541
- 35 USC 102 Novelty (BERT): 0.4991852125032749
- Combined Prediction Score: 0.7127885773771462
- Mean Citation Score: 200.15888
- Max Citation Score: 204.1207
- Similarity Product: 128.98550319671034

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test